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Summary These studies were undertaken to assess the relative expression and autocrine activation of the epidermal growth factor receptor
(EGFR) in normal and transformed prostatic epithelial cells and to determine whether EGFR activation plays a functional role in androgen-
stimulated growth of prostate cancer cells in vitro. EGFR expression was determined by Western blot analysis and ELISA immunoassays.
Immunoprecipitation of radiophosphorylated EGFR and evaluation of tyrosine phosphorylation was used to assess EGFR activation. The
human androgen-independent prostate cancer cell lines PC3 and DU145 exhibited higher levels of EGFR expression and autocrine
phosphorylation than normal human prostatic epithelial cells or the human androgen-responsive prostate cancer cell line LNCaP. PC3 and
DU145 cells also showed higher levels of autonomous growth under serum-free defined conditions. Normal prostatic epithelial cells
expressed EGFR but did not exhibit detectable levels of EGFR phosphorylation when cultured in the absence of exogenous EGF. Addition of
EGF stimulated EGFR phosphorylation and induced proliferation of normal cells. LNCaP cells exhibited autocrine phosphorylation of EGFR
but did not undergo significant proliferation when cultured in the absence of exogenous growth factors. A biphasic growth curve was observed
when LNCaP cells were cultured with dihydrotestosterone (DHT). Maximum proliferation occurred at 1 nM DHT with regression of the growth
response at DHT concentrations greater than 1 nm. However, neither EGFR expression nor phosphorylation was altered in LNCaP cells after
androgen stimulation. In addition, DHT-stimulated growth of LNCaP cells was not inhibited by anti-EGFR. These studies show that autocrine
activation of EGFR is a common feature of prostatic carcinoma cells in contrast to normal epithelial cells. However, EGFR activation does not
appear to play a functional role in androgen-stimulated growth of LNCaP cells in vitro.
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The prostate gland is dependent on the presence of circulating
androgens to maintain its normal structure and function (Butler
and Schade, 1958; Lee and Sensibar, 1978; Isaacs, 1984).
Likewise, prostatic neoplasms are androgen-sensitive tumours that
undergo regression after chemical or surgical androgen ablation
(Scott et al, 1980; Geller et al, 1988; Deneshagari and Crawford,
1993). However, the vast majority of disseminated prostatic
adenocarcinomas recur and progress in the androgen-depleted
environment (Lepor et al, 1982). Although new and more sophisti-
cated methods ofinducing androgen ablation have been developed
in recent years, the basic premise of anti-androgen therapy in the
treatment ofprostate cancer has remained largely unchanged since
the pioneering work of Huggins and Hodges in the 1940s
(Huggins and Hodges, 1941). After recurrence in the androgen-
depleted host, most disseminated, androgen-independent prostatic
tumours are resistant to conventional chemotherapy and radiation
treatment. Therefore, understanding of the mechanisms of
androgen-independent growth ofprostate cancers with the hope of
developing effective interventions against metastatic androgen-
independent tumours is a major area of interest in the field of
prostate cancer research.
Received 30April 1997
Revised 1 July 1997
Accepted 8 July 1997
Correspondence to: C Lee
The epidermal growth factor receptor (EGFR) is a 170-kDa
transmembrane glycoprotein that has been identified in normal,
hyperplastic and malignant prostatic epithelium (Maygarden et al,
1992; Ching et al, 1993; Ibrahim et al, 1993). The binding ofEGF,
TGF-a or amphiregulin results in tyrosine phosphorylation of
EGFR and activation of downstream signal transduction pathways
(Aaronson, 1991; Pellicci et al, 1992; Leevers et al, 1994). Results
ofseveral recent investigations have demonstrated increased TGF-
x expression and activation of EGFR in human and non-human
prostatic carcinomas (Hofer et al, 1991; Fong et al, 1992; Kaplan
et al, 1996). Autocrine activation ofEGFR has been proposed as a
mechanism to support neoplastic growth and tissue invasiveness of
transformed prostatic epithelial cells (Hofer et al, 1991; Fong et al,
1992; Jarrard et al, 1994; Turner et al, 1996). However, the relative
level of EGFR expression in normal prostatic epithelial cells as
well as in androgen-responsive and androgen-independent
prostatic tumourcells has not been clearly defined. In addition, the
functional role ofEGFR activation in androgen-stimulated growth
of prostate cancers has not been determined. The present studies
were undertaken to define the relative expression and activation of
EGFR in normal and malignant prostatic epithelial cells. In addi-
tion, EGFR expression and autocrine phosphorylation was deter-
mined in androgen-responsive and androgen-independent prostate
cancer cells. Further studies were undertaken to determine the
functional role ofEGFR activation in androgen-stimulated growth
ofLNCaP cells in vitro.
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MATERIALS AND METHODS
Cell lines
The androgen-independent prostatic carcinoma cell lines PC3 and
DU145 were generously provided by Drs E Kaighn (Experimental
Carcinogenesis Laboratory, NIH) and D Mickey (Duke University
Medical Center, Durham, NO, USA) respectively. The androgen-
responsive prostatic carcinoma cell line LNCaP was purchased
from the American Type Culture Collection (Rockville, MD,
USA). Stock cultures of the respective cell lines were maintained
in RPMI-1640 medium containing 10% fetal bovine serum (FBS)
and penicillin (100 U ml-')/streptomycin (100 ug ml-') (P/S).
Normal prostatic epithelial cells were isolated from fresh prostatic
tissue obtained from organ donors ofless than 35 years of age and
established in primary culture. Serial sections of prostatic tissue
were examined microscopically after staining with haematoxylin
and eosin to assure the absence of carcinoma or benign hyper-
plasia. Epithelial cells were isolated by enzymatic and mechanical
dissociation of prostatic tissue followed by Percoll gradient
centrifugation of the resulting cell suspension as previously
described (Kozlowski et al, 1988; Sherwood et al, 1989). Isolated
epithelial cells were cultivated in complete WAJC 404 medium
which consisted ofWAJC 404 medium supplemented with bovine
pituitary extract (30 ug ml-', Upstate Biotechnology, Lake Placid,
NY, USA), EGF (10 ng ml-', Upstate Biotechnology), cholera
toxin (10 ng ml-', Sigma Chemical, St Louis, MO, USA), prolactin
(3 ng ml-', Sigma), Redu-Ser II (insulin 5 jig ml-', transferrin
5 jg ml', sodium selenite 5 ng ml-', bovine serum albumin
500 jg ml-', oleic acid 4.3 jg ml-', Upstate Biotechnology) and
P/S. Normal epithelial cells were used in experiments after one or
two serial passages. Primary cultures of prostatic epithelial cells
are designated as El throughout the text.
Antibodies and growth factors
Monoclonal antibodies 225 and 528 raised against the human
epidermal growth factor receptor (EGFR) were generously
provided by Dr J Mendelsohn (Memorial Sloan-Kettering Cancer
Center) and were prepared as previously outlined (Kawamoto et al,
1983; Gill et al, 1984). Anti-EGFR clone LA22, monoclonal anti-
phosphotyrosine clone 4G10 and EGF were purchased from
Upstate Biotechnology. Dihydrotestosterone (DHT) was
purchased from Sigma.
Assessment of cell numbers
Cells (1-2 x 104 per well) were plated in 24-well plates and
allowed to adhere overnight (16-18 h). The following day, cultures
were washed three times with phosphate-buffered saline (PBS, pH
7.4) and experimental samples were added to respective wells.
Day 0 cell counts were performed to determine plating efficiency.
Cells were cultured (37°C, 5% carbon dioxide) for 6 days and
media were replaced on days 2 and 4. The cells were harvested
using 0.25% trypsin/0.1% EDTA (Life Technologies, Grand
Island, NY, USA) and counted using a Coulter counter (Coulter
Electronics, Hialeah, FL, USA).
Western blotting and ELISA immunoassays
For Western blotting, cells were plated (2 x 105 per well) in six-
well plates and grown to 80-90% confluency. The cells were
Table 1 Proliferation of normal and transformed prostatic epithelial cells in
the presence and absence of EGF
Cell line Cells per well x 10-4
Day 0 No EGF EGF Complete media
El 1.2±0.2 1.4±0.3 3.6±0.4* 6.0±0.4*
LNCaP 1.1 ± 0.1 1.2 ± 0.4 2.5 ± 0.4* 6.1 ± 0.5*
DU145 1.5 ± 0.3 4.2 ± 0.3* 6.5 ±0.7* 13.9± 2.6*
PC3 1.0 ± 0.2 8.3 ± 1.2* 9.9 ±0. 12.2± 1.8*
Cells were cultured under defined conditions in 24-well plates for 6 days and
counted with a Coulter counter. Day 0 cell counts were performed to
determine plating efficiency and provide a reference point for assessing
cellular proliferation. In additional wells, cells were cultured in defined EGF-
free medium or with EGF (20 ng ml-') to assess EGF-induced proliferation.
As a positive control, cells were cultured with RPMI-1640 media containing
10% FBS (PC3, DU145, LNCaP) or complete WAJC 404 (normal epithelial
cells). El refers to primary cultures of normal prostatic epithelial cells.
n = 8-12 per group. *P < 0.05 compared with Day 0 control.
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Figure 1 Effect of DHT on the proliferation of LNCaP cells. LNCaP cells
(2 x 104 per well) were plated in 24-well plates and allowed to adhere
overnight. Cells were cultured for 6 days in RPMI-1640 media supplemented
with 10% charcoal-stripped FBS and varying concentrations of DHT as
indicated. Anti-EGFR clone 528 (20 nM) was added to additional wells to
determine the effect of anti-EGFR on DHT-stimulated growth of LNCaP cells.
Non-specific IgG served as a control. Cells were detached from the culture
surface with trypsin/EDTA and counted with a Coulter counter to determine
cell numbers in each group. Values represent the mean ± s.e.m. n = 8-12 per
group
harvested using 1.5 mM EDTA in PBS followed by gentle scraping
with the plunger of a l-ml syringe and were counted using a
haemocytometer. The cells were washed (3x) with cold PBS,
disrupted using lysis buffer (1% Triton X-100, 10 mM Tris-HCl
(pH 7.0), 1.5 mi EDTA, 1 mm phenylmethylsulphonyl fluoride
(PMSF), 1 mm sodium vanadate, 1 gg ml-' leupeptin, pepstatin
and aprotinin) at aconcentration of 1 x 107 cells per 0.5 ml oflysis
buffer, and the Triton-soluble supernatant was harvested after
centrifugation at 14 000g for 10 min. Protein concentration was
determined using the Coomassie protein assay (Pierce Chemical,
Rockford, IL, USA). Proteins (200 ,ug per lane) were separated by
SDS-PAGE and electrophoretically transferred to nitrocellulose
membranes (0.2 jim, Bio-Rad, Hercules, CA, USA) using a
transfer buffer consisting of 192 mM glycine, 25 mM Tris-HCl and
20% methanol. Blots were blocked for 2-4 h in 5% non-fat dry
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Figure 2 Relative expression of EGFR by normal (El) and malignant
prostatic epithelial cells. Cell lysates were prepared and 200 ,g of protein
from each cell type was separated by SDS-PAGE. EGFR were detected by
Western blotting using monoclonal anti-EGFR clone LA22. Molecular weight
markers are indicated in kDa
Table 2 Relative expression of EGFR by prostatic cell lines
Cell line Densitometry ELISA
(c.p.m.) (receptors per cell x 14)
PC3 254 ± 28* 20.9 ±3.1 *
DU145 342 ± 39* 25.2 ± 3.9*
LNCaP 68 ±6 6.3 ± 0.9
El 89±7 7.9±0.5
EGFR levels were measured by Western blotting. Proteins (200 ,ug per lane)
were separated by SDS-PAGE, immunoblotted with anti-EGFR 528 and
visualized using the ECL system. Band intensity was quantitated by
densitometry and results reflect the mean ± s.e.m. for three separate
determinations. For the ELISA, cells were cultured in 10% FBS, cell lysates
were prepared and the assay was performed as outlined in Materials and
methods. The results reflect the mean ± s.e.m. for at least six separate wells
for each cell type. *Significantly (P < 0.05) greater EGFR than LNCaP cells
and normal prostatic epithelial cells.
milk reconstituted in PBS and incubated at 25°C with primary
antibody for 16-18 h. The blots were washed (3x) with TTBS
(0.05% Tween 20, 50 mm Tris-HCl, 200 mm sodium cholride) and
incubated at 25°C with horseradish peroxidase (HRP)-conjugated
secondary antibody for 1 h. Immunoreactive proteins were visual-
ized using the enhanced chemiluminescence (ECL) system
(Amersham, Arlington Heights, IL, USA). Band intensities were
quantitated using the Ambis Image Acquisition and Analysis
System (Ambis, San Diego, CA, USA).
For the ELISA assay, samples were prepared as outlined above
for Western blotting except that manufacturer-supplied antigen
extraction buffer was used to prepare cell lysates. Cells (2 x 107 per
0.5 ml of antigen extraction buffer) were lysed, centrifuged
(14 000 g for 10 min) and the supematant was harvested. Samples
were diluted with antigen extraction buffer to achieve protein
concentrations of 0.4-50 jig ml-'. The human EGFR ELISA was
purchased from Oncogene Science (Uniondale, NY, USA) and the
assay was performed according to the manufacturer's instructions.
Briefly, samples (0.4-50 jig ofprotein ml-') were added to 96-well
microtitre wells precoated with monoclonal anti-EGFR and
incubated at 37°C for 3 h. EGFR standards of 0-80 fmol ml-' as
provided by the manufacturer were added to wells in duplicate for
development of a standard curve. The wells were washed six times
using a plate washer (Bio-Rad Model 1250) followed by addition of
rabbit anti-EGFR and incubation at 25°C for 1 h. After washing,
HRP-conjugated goat anti-rabbit IgG was added and plates were
incubated at 25°C for 1 h. A sulphuric acid solution (2.5 N) was
added to each well to stop the peroxidase reaction, and samples were
analysed with a microplate reader (Bio-Rad Model 3550) at490 nm.
Labelling of proteins with 32p;
Cells were plated (3 x 105 cells per well) in six-well plates and
allowed to adhere overnight. The following day, cells were washed
three times with PBS and cultured in serum-free, growth factor-
free media for 24 h. Cells were then washed three times with
phosphate-free Dulbecco's modified Eagle Medium (DMEM) and
cultured in phosphate-free DMEM containing 32p, (0.4,Ci per
well, Amersham) and experimental additives for 24 h. Cells were
then washed three times with PBS and 2 ml of lysis buffer was
added to each well. Samples were harvested and cleared by
centrifugation (2000 g for 10 min). In additional wells, cells were
detached from the culture surface using 0.25% trypsin/0.1% EDTA
and counted with a Coulter counter to quantitate cell numbers in
each group. Immunoprecipitation of radiophosphorylated EGFR
was performed using 500 ,ug ofprotein from each group.
Immunoprecipitation
Protein A Sepharose 4B Fast Flow beads (Sigma Chemical) were
combined with anti-EGFR 528 by incubating 100gl of 20% (v/v)
beads with 2 jg ofantibody at4°C for 16-18 h. Beads were washed
three times with cold PBS and added to cell lysates (1 x 106cells per
sample). Samples were incubated at 4°C for 16-18 h with shaking,
and beads were washed three times withcold Triton-free lysis buffer
followed by elution of proteins with Laemmli buffer (0.5 M Tris-
HCl, 2% sodiumdodecyl sulphate) andboiling. Immunoprecipitated
proteins were separated by SDS-PAGE.
Statistics
Statistical analyses were performed using one-way analysis of
variance followed by Student's t-test. A value of P < 0.05 was
considered to be statistically significant.
RESULTS
Autonomous and EGF-stimulated growth of benign and
malignant prostatic epithelial cells
The proliferation ofbenign and malignant prostatic epithelial cells
was evaluated in the presence and absence of EGF (Table 1).
Normal prostatic epithelial cells established in primary culture (El)
did not exhibit significant proliferation when cultured in serum-
free WAJC 404 medium devoid ofEGF. Cultivation ofnormal cells
in defined media supplemented with EGF or in complete WAJC
404 medium resulted in twofold and fivefold (P < 0.05) increases
in cell number, respectively, compared with EGF-free controls.
LNCaP cells did not exhibit growth when cultured in EGF-free
medium. However, addition of EGF more than doubled (P < 0.05)
LNCaP proliferation compared with EGF-free controls and a
greater than fourfold increase in LNCaP proliferation was observed
when cells were cultured with medium containing 10% fetal
bovine serum (FBS). DU145 and PC3 cells exhibited significant
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Figure 3 Effect of DHT and EGF on EGFR expression in prostatic
carcinoma cells. Cells were cultured for 24 h in media containing Redu-Ser II
alone or Redu-Ser II supplemented with EGF (30 ng ml-') or DHT (1 nM).
Cells were harvested, quantitated and lysed (1 x 107 per 0.5 ml of lysis
buffer). Proteins (200 ,ug per lane) were separated by SDS-PAGE and
detected by Western blotting with anti-EGFR clone LA22
LNCaP [DHT (nM)]
PC3 DU145 0 0.001 0.01 0.1 1 10
Figure 4 Lack of DHT-induced alteration in EGFR expression in LNCaP
cells. LNCaP cells were cultured in media supplemented with 10% charcoal-
stripped FBS and DHT (0-10 nM) for 24 h. Cell lysates were prepared and
proteins (200 ,ug per lane) were separated by SDS-PAGE. EGFR were
detected by Western blotting. Equivalent protein (200 ,ug per well) from PC3
and DU145 cells were run in parallel for comparison
3.4-fold and 7.6-fold increases in cell number, respectively,
compared with day 0 controls when cultured in defined, growth
factor-free media. Addition ofEGF further enhanced the growth of
DU145 and PC3. The highest level of growth was observed when
PC3 and DU145 were cultured in media containing 10% FBS.
Additional studies were undertaken to assess the growth
response of LNCaP cells to DHT and to determine the effect of
anti-EGFR on DHT-stimulated proliferation of LNCaP cells
(Figure 1). A biphasic growth curve was observed with peak cell
growth occurring at a DHT concentration of 1 nM with regression
ofDHT-enhanced proliferation at DHT concentrations greater than
1 nm. Addition of anti-EGFR 225 to LNCaP cells cultured with
DHT did not significantly alter LNCaP cell proliferation compared
with cells cultured in the absence of anti-EGFR. As a control,
LNCaP cells were also cultured with non-specific IgG, which also
did not alter DHT-enhanced proliferation ofLNCaP cells.
EGF receptor expression in normal and transformed
prostatic epithelial cells
The relative expression of EGFR in different prostatic cells was
determined by Western blot analysis (Figure 2). The androgen-
independent cell lines PC3 and DU145 showed a higher level of
EGFR expression than normal epithelial cells (El) or LNCaP
Table 3 Relative expression of EGFR in LNCaP cells incubated with DHT
DHT (nM) Densitometry ELISA
(c.p.m.) (receptors per cell x 10-4)
0 92±5 4.6±0.6
0.001 80 ± 6 4.2+ 0.8
0.01 86 ± 9 5.6+ 0.5
0.1 90±11 4.3±1.1
1 96±7 4.0±0.8
10 98±12 4.8±0.7
LNCaP cells were cultured in the presence of DHT at concentrations of
0-10 nm for 24 h. Cells were harvested, counted and lysates were prepared.
Proteins (200gg per lane) were separated by SDS-PAGE, and EGFR bands
were visualized by immunoblotting with anti-EGFR. EGFR expression was
quantitated by densitometric analysis of Western blots. EGFR in cell lysates
was also quantitated by ELISA. ELISA and Western blot results represent
data from at least three separate determinations for each group. Values are
expressed as the mean ± s.e.m.
cells. Band intensity ofWestern blots were quantitated by densito-
metry (Table 2). Densitometric analysis showed that PC3 and
DU145 expressed 3.7-fold and 5.0-fold higher levels of EGFR
than LNCaP respectively. Compared with normal epithelial cells,
PC3 and DU145 expressed 2.9-fold and 3.8-fold greater levels of
EGFR. Comparison of EGFR expression between LNCaP and
normal epithelial cells did not show a statistically significant
difference.
The relative level ofEGFRexpression in prostatic cells was also
quantitated by ELISA (Table 2). The level of EGFR expression in
PC3 and DU145, cells was 3.3-fold and 4.2-fold greater, respec-
tively, than that observed in LNCaP. Compared with normal
epithelial cells, 2.6-fold and 3.3-fold greater levels of EGFR
expression were observed in PC3 and DU145 cells, respectively.
Effect of DHT and EGF on EGFR expression in prostatic
tumour cells
Examination of EGFR expression in the presence of exogenous
EGF or DHT showed that EGF down-regulated EGFR expression
in LNCaP and PC3 cells while DHT at 1 nm had no effect (Figure
3). Dose-response studies showed that DHT at concentrations of
0.001-10 nM did not alter EGFR expression in androgen-respon-
sive LNCaP cells (Figure 4). For comparison, PC3 and DU145
cells were run in parallel lanes. As previously shown, PC3 and
DU145 cells expressed higher levels of EGFR than LNCaP. The
quantitative analysis of EGFR bands on Western blots by densito-
metry or assessment ofEGFR content by ELISA also showed that
DHT at 0.001-10 nM did not significantly alter EGFR expression
in androgen-responsive LNCaP cells (Table 3).
Phosphorylation of EGFR in benign and malignant
prostatic epithelial cells
Immunoprecipitation studies were conducted after labelling of
EGFR with 32p; under serum-free, growth factor-free conditions
(Figure 5A). The prostatic tumour cell lines PC3, DU145 and
LNCaP exhibited autocrine phosphorylation of the EGFR (Figure
5A). Densitometric analysis showed that DU145 (212 c.p.m.) and
PC3 (182 c.p.m.) possessed higher levels of autocrine EGFR
phosphorylation than LNCaP (72 c.p.m.). The relative tyrosine
phosphorylation of EGFR in LNCaP, PC3 and DU145 cells was
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Figure 5 Relative autocrine phosphorylation of EGFR in prostatic tumour
cells. (A) DU145, PC3 and LNCaP cells were cultured in phosphate-free
media containing Redu-Ser II and 32p; for 24 h. Cells lysates were prepared,
EGFR were immunoprecipitated, and radiolabelled EGFR were resolved on
7.5% SDS-PAGE gels. Proteins were visualized by fluorography. (B) DU145,
PC3 and LNCaP cells were cultured in media supplemental in the Redu-Ser
11 for 24 h. Cell lysates were prepared. EGFR were immunoprecipitated and
Western blotting was performed with anti-phosphotyrosine clone 4G10
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Figure 6 Comparison of autocrine phosphorylation of EGFR in normal
prostatic epithelial cells and DU145 cells. Normal cells (El) and DU145 cells
were cultured in phosphate-free media supplemented with Redu-Ser II and
32p for 24 h. EGF, anti-EGFR and mouse IgG were added to cultures 6 h
before harvesting cells. Cell lysates were prepared, EGFR
immunoprecipitated and the immunoprecipitate separated by SDS-PAGE.
32P-labelled proteins were detected by fluorography
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Figure 7 Effect of DHT on EGFR phosphorylation in LNCaP cells.
(A) LNCaP cells were cultured with DHT and 32p for 24 h. Cell lysates were
prepared and EGFR were immunoprecipitated with anti-EGFR 528. EGFR
were resolved on 7.5% SDS-PAGE gels and visualized using fluorography.
(B) LNCaP cells were incubated in media containing 5% charcoal-stripped
FBS and DHT (0-10 nM) for 24 h. Cell lysates were prepared, proteins
immunoprecipitated with anti-EGFR clone 528 and separated by SDS-PAGE.
Western blots were performed using anti-phosphotyrosine clone 4G10
also assessed by immunoprecipitation of EGFR followed by
Western blotting with anti-phosphotyrosine. PC3 (75 c.p.m.) and
DU145 (81 c.p.m.) showed higher levels of EGFR tyrosine phos-
phorylation than LNCaP (52 c.p.m.) (Figure 5B).
Analysis of EGFR activation in normal prostatic epithelial cells
showed a lack of EGFR phosphorylation when normal cells were
cultured in the absence of exogenous growth factors but showed
that addition ofEGF stimulated EGFR phosphorylation (Figure 6).
For comparison, parallel studies were performed using DU145
cells. DU145 cells exhibited autocrine activation of EGFR which
was further enhanced by EGF. Anti-EGFR reduced autocrine
activation of EGFR. As a control, non-specific IgG did not alter
EGFR activation compared with serum-free, antibody-free
controls (Figure 6).
Effect of DHT on EGFR phosphorylation
The effect of DHT (0-10 nM) on total EGFR phosphorylation in
LNCaP cells was determined by immunoprecipitation of radio-
phosphorylated EGFR (Figure 7A). Densitometric analysis of
three separate runs showed no change in total EGFR phosphoryla-
tion when DHT was added to the culture media. The effect ofDHT
on EGFR tyrosine phosphorylation in LNCaP cells was studied by
immunoprecipitation of EGFR followed by Western blotting with
anti-phosphotyrosine (Figure 7B). No difference in the level of
EGFR tyrosine phosphorylation was observed when LNCaP cells
were cultured in the presence of 0-10 nM DHT as determined by
densitometry for three separate runs.
DISCUSSION
The treatment of metastatic prostate cancer is complicated by the
ability of prostatic tumour cells to escape conventional anti-
androgen therapy. Most disseminated prostatic tumours undergo
regression after surgical or chemical androgen ablation. However,
tumour relapse and progression occurs in the vast majority of
cases. Tumour regrowth is mediated through androgen-
independent mechanisms, which are currently poorly understood.
Therefore, understanding of the cellular and molecular mecha-
nisms involved in androgen-independent growth and progression
of prostate cancers is a key step in developing rational treatment
approaches to this disease.
The EGFR and its ligands, EGF and TGF-a, have been identi-
fied in benign and malignant prostatic tissues and cells (Wilding et
al, 1989; Connolly and Rose, 1991; Hofer et al, 1991; Fong et al,
1992; Maygarden et al, 1992; Ching et al, 1993; Ibrahim et al,
1993). The functional role of the TGF-a-EGFR interaction has
been demonstrated in cultured prostate cancer cells (Hofer et al,
1991; Fong et al, 1992). Results from the present study demon-
strated the autocrine activation of the EGFR in all of the prostatic
tumour cell lines studied. In contrast, normal prostatic epithelial
cells did not exhibit autocrine activation of the EGFR. These
results indicate that autocrine phosphorylation of EGFR is a
common finding in cultured prostatic cancer cells and appears to
be a defining characteristic ofthe transformed phenotype. In addi-
tion, the androgen-independent cell lines PC3 and DU145 exhib-
ited higher levels of EGFR expression and phosphorylation than
LNCaP cells. PC3 and DU145 cells also demonstrated higher
levels of autonomous growth than LNCaP cells. Previous studies
have shown that the autonomous growth of DU145 and PC3 cells
is inhibited by anti-EGFR (Connolly and Rose, 1991; Hofer et al,
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1991; Fong et al 1992). We have demonstrated that TGF-x is the
primary ligand mediating autocrine activation ofEGFR. TGF-x is
present in conditioned media from PC3 and DU145 cultures and
anti-TGF-ax, but not anti-EGF, will inhibit the autonomous growth
of PC3 and DU145 cells (Hofer et al, 1991). Taken together, these
results demonstrate that autocrine activation of the EGFR is a
common feature oftransformed prostatic epithelial cells and plays
a functional role in androgen-independent growth in vitro.
Some studies have shown that EGFR expression is modestly
increased in LNCaP cells and the androgen-responsive ALVA-101
cell line after androgen stimulation (Schuurmans et al, 1988; Liu
et al, 1993). ALVA-101 cells also exhibited a small increase in
TGF-ax expression after incubation with DHT (Liu et al, 1993).
Rukstalis and colleagues (Brass et al, 1995) observed up-regula-
tion of EGFR expression and binding affinity after androgen
stimulation of PC3 cells transfected with an androgen receptor
expression vector. However, other investigators have shown that
TGF-x (Wilding et al, 1989; Connolly and Rose, 1990) and EGF
(Connolly and Rose, 1990) expression are not increased in LNCaP
cells after androgen stimulation. Results from additional studies
have shown that EGFR expression was unchanged by androgen
stimulation of LNCaP cells (McDonald and Habib, 1992) or the
Dunning rat model ofprostatic carcinoma (Damber et al, 1995). In
the present study, we confirm and extend these latter observations
by showing that EGFR phosphorylation is not altered by the
presence ofDHT. We examined EGFR phosphorylation in LNCaP
cells over a wide range of DHT concentrations and observed that
DHT does not alter EGFR phosphorylation. We also found that
DHT-induced proliferation ofLNCaP cells is not inhibited by anti-
EGFR 225. Our previous studies (Hofer et al, 1991; Fong et al,
1992) demonstrated that PC3 and DU145 proliferation is inhibited
by anti-EGFR 225. These findings indicate that EGFR activation is
not likely to play a role in DHT-induced growth of LNCaP cells.
This is in contrast to the findings of Liu and co-workers (1993)
who have reported that androgen-stimulated growth of ALVA 101
cells is inhibited by anti-EGFR.
The relative level of EGFR expression in prostate cancer and in
normal prostatic epithelium remains controversial. Several reports
have demonstrated higher levels of EGFR expression in prostate
cancer (Morris and Dodd, 1990; Ching et al, 1993; Montone and
Tomaszewski, 1993; Glynn-Jones et al, 1996) compared with
normal prostate. In some studies, the level of EGFR expression
correlated with increased nuclear size (Montone and Tomaszewski,
1993) and cellular dedifferentiation (Morris and Dodd, 1990;
Glynn-Jones et al, 1996). EGFR expression has also been corre-
lated with higher histological grade, increased S-phase fraction
and poorer prognosis of prostate cancers (Visacorpi et al, 1992).
However, other immunohistochemical investigations have shown
greater EGFR expression in normal and hyperplastic prostate
compared with prostate cancer (Maygarden et al, 1992; Mellon et
al, 1992; Ibrahim et al, 1993). Our study demonstrated a higher
level of EGFR expression in the androgen-independent PC3 and
DU145 cell lines than in LNCaP cells or in normal epithelial cells.
Comparison of LNCaP and in normal epithelia showed almost
equivalent levels of EGFR expression. Higher levels of EGFR
expression in DU145 and PC3 compared with LNCaP have been
reported at the transcriptional level (Morris and Dodd, 1990; Ching
et al, 1993) and by ligand binding (Davies and Eaton, 1989). Our
results extended those findings by showing increased EGFR
expression at the translational level in PC3 and DU145 cells. In
addtiion, our studies demonstrated that androgen-independent but
not androgen-sensitive, prostatic tumour cell lines express higher
levels ofEGFR than normal prostatic epithelial cells. None ofthe in
vivo studies have adequately addressed the issue of relative EGFR
expression in androgen-sensitive and androgen-independent
prostate cancer, although Davies and Eaton (1989) have reported an
inverse relationship between EGF binding and androgen receptor
expression in homogenized specimens of prostatic carcinoma.
Results of the present study showed that elevated expression
and activation of EGFR were associated with the androgen-
independent phenotype.
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